Has Wall Street gone a bit overboard punishing ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)?
ACAD receives BTD in dementia-related psychosis; Initiates DRP phase 3 trial; Phase 2 SERENE trial discontinued.
Investors are pricing in some optimism in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), after the drug maker announced that the FDA has granted Breakthrough Therapy Designation to …
